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Selective hybridization and capture of KRAS DNA from plasma and blood using 
ion-tagged oligonucleotide probes coupled to magnetic ionic liquids 
Abstract 
Detection of circulating tumor DNA (ctDNA) presents several challenges due single-nucleotide 
polymorphisms and large amounts of background DNA. Previously, we reported a sequence-specific DNA 
extraction procedure utilizing functionalized oligonucleotides called ion-tagged oligonucleotides (ITOs) 
and disubstituted ion-tagged oligonucleotides (DTOs). ITOs and DTOs are capable of hybridizing to 
complementary DNA for subsequent capture by a magnetic ionic liquid (MIL) through hydrophobic 
interactions, π-π stacking, and fluorophilic interactions. However, the performance of the ITOs and DTOs 
in complex sample matrices has not yet been evaluated. In this study, we compare the amount of KRAS 
DNA extracted using ITO and DTOs from saline, 2-fold diluted plasma, 10-fold diluted plasma, and 10-fold 
diluted blood. We demonstrate that ITO/DTO-MIL extraction is capable of selectively preconcentrating 
DNA from diluted plasma and blood without additional sample preparation steps. In comparison, 
streptavidin-coated magnetic beads were unable to selectively extract DNA from 10-fold diluted plasma 
and 10-fold diluted blood without additional sample clean-up steps. Significantly more DNA could be 
extracted from 2-fold diluted plasma and 10-fold diluted blood matrices using the DTO probes compared 
to the ITO probes, likely due to stronger interactions between the probe and MIL. The ability of the DTO-
MIL method to selectively preconcentrate small concentrations of DNA from complex biological matrices 
suggests that this method could be beneficial for ctDNA analysis. 
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Abstract 7 
 Detection of circulating tumor DNA (ctDNA)  presents several challenges due single-8 
nucleotide polymorphisms and large amounts of background DNA. Previously, we reported a 9 
sequence-specific DNA extraction procedure utilizing functionalized oligonucleotides called ion-10 
tagged oligonucleotides (ITOs) and disubstituted ion-tagged oligonucleotides (DTOs). ITOs and 11 
DTOs are capable of hybridizing to complementary DNA for subsequent capture by a magnetic 12 
ionic liquid (MIL) through hydrophobic interactions, π-π stacking, and fluorophilic interactions. 13 
However, the performance of the ITOs and DTOs in complex sample matrices has not yet been 14 
evaluated. In this study, we compare the amount of KRAS DNA extracted using ITO and DTOs 15 
from saline, 2-fold diluted plasma, 10-fold diluted plasma, and 10-fold diluted blood. We 16 
demonstrate that ITO/DTO-MIL extraction is capable of selectively preconcentrating DNA from 17 
diluted plasma and blood without additional sample reparation steps. In comparison, 18 
streptavidin-coated magnetic beads were unable to slectively extract DNA from 10-fold diluted 19 
plasma and 10-fold diluted blood without additional s mple clean-up steps.  Significantly more 20 
DNA could be extracted from 2-fold diluted plasma and 10-fold diluted blood matrices using the 21 
DTO probes compared to the ITO probes, likely due to stronger interactions between the probe 22 
and MIL. The ability of the DTO-MIL method to selectively preconcentrate small concentrations 23 
of DNA from complex biological matrices suggests that this method could be beneficial for 24 
ctDNA analysis.  25 
 26 
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 35 
1. Introduction 36 
 Circulating tumor DNA (ctDNA) is fragmented tumor-derived DNA found in blood 37 
originating from tumor cells that have undergone apoptosis or necrosis.[1]  Detection of ctDNA 38 
from blood has massive potential to supplement or replace invasive tissue biopsies for cancer 39 
diagnosis, treatment, and the monitoring of residual isease.[2] However, during the early stages 40 
of cancer or after cancer treatment, ctDNA fragments are present in low amounts relative to 41 
wild-type DNA with mutation abundances potentially less than 0.01%.[3] Large amounts of 42 
background DNA can mask low abundance mutant fragments causing false negative results.[2] 43 
Furthermore, ctDNA fragments are prone to single-nucleotide polymorphisms (SNPs).[4] The 44 
KRAS gene is particularly prone to SNPs, typically around codon 12 and 13 in exon 2, which can 45 
impair the guanosine triphosphatase activity of the KRAS protein resulting in cellular 46 
proliferation.[5,6] The presence of certain KRAS SNPs have also been correlated to the success 47 
of anti-EGFR therapy making it crucial to distinguish SNPs from wild-type DNA.[7,8] 48 
Therefore, ctDNA analysis requires sequence-specific detection in order to distinguish low 49 
concentrations of SNPs from complex matrices.  50 
There are several polymerase chain reaction (PCR) methods for sequence-specific 51 
amplification and detection.[2,9] However, large amounts of background DNA may result in 52 
false positives due to mishybridization or mask target DNA fragments.[10] Wild-type DNA can 53 
be co-amplified with ctDNA when using similar primer sets. PCR blockers, such as peptide 54 
nucleic acids (PNAs) or locked nucleic acids (LNAs), can limit amplification of wild-type 55 
DNA.[11–13] However, PNAs and LNAs are expensive, and their ability to discriminate 56 
between the wild-type and mutant fragment relies heavily on the positioning and sequence of the 57 
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probe.[14,15] Co-amplification at lower denaturation temperature (COLD) PCR can also limit 58 
co-amplification of wild-type DNA by carefully optimizing the annealing temperature to ensure 59 
that wild-type DNA remains a duplex during the annealing and extension step.[16] While 60 
COLD-PCR is useful for selectively amplifying known and unknown mutations, the critical 61 
temperature of the mutant fragment must be lower than the wild-type DNA for selective 62 
amplification, which prevents approximately 30% of all mutations from being detected.[17] In 63 
addition, all PCR methods require highly pure DNA for amplification to occur, and blood and 64 
plasma components such as IgG or hemoglobin can inhibit PCR.[18,19] Therefore, sequence-65 
specific DNA extraction step is needed in order to limit the co-extraction of non-target DNA and 66 
PCR inhibitors. 67 
Sequence-specific DNA extractions can supplement PCR amplification by preventing 68 
large amounts of background DNA from contaminating the reaction. Commercial methods for 69 
such extractions often rely on streptavidin-coated magnetic beads and biotinylated 70 
oligonucleotides.[1,20,21] Target DNA can be captured using streptavidin-coated magnetic 71 
beads due to streptavidin’s exceptional affinity for biotin (Kd = 4×10
-14 M).[22] However, 72 
streptavidin-coated magnetic beads are prone to aggregation and sedimentation, which can 73 
reduce extraction efficiencies and clog microfluidic devices.[23,24] Other sequence-specific 74 
extraction methods include the use of oligonucleotide-modified monoliths; however, these 75 
procedures can currently achieve picomolar detection limits where most ctDNA fragments are 76 
present at femtomolar concentrations or lower.[25–27] Oleoyl-modified oligonucleotides have 77 
also been used for sequence-specific DNA extractions. DNA can be selectively hybridized to the 78 
oleoyl-modified oligonucleotide and be contained within reverse micelles of 79 
diauroylphosphatidylcholine and 1-hexanol.[28] It was demonstrated that over 60% of the target 80 
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DNA was extracted using the oleoyl-modified oligonucleotides whereas only 6% and 4% of the 81 
1 nt and 2 nt mismatch fragments, respectively, were extracted. However, a lengthy extraction 82 
step (i.e., 3 h) is required to form the reverse micelles as significant agitation can disrupt the 83 
interface between the aqueous and organic phases. In addition, this method has never been used 84 
to extract clinically-relevant concentrations of ctDNA nor has it been applied to a complex 85 
matrix.  86 
A recent and promising alternative to commercial sequence-specific DNA extraction 87 
approaches is the use of magnetic ionic liquids (MILs).[29] MILs are a subclass of ionic liquids 88 
(ILs) that contain a paramagnetic component in either e cation or anion allowing them to be 89 
dispersed as droplets and be rapidly collected using an external magnet.[30,31] Hydrophobic 90 
manganese(II)-based MILs, in particular, have been fou d to poorly extract DNA with extraction 91 
efficiencies less than 2%.[29,32,33] A series of DNA extraction probes termed ion-tagged 92 
oligonucleotides (ITOs) have been designed to contain an imidazolium headgroup that interacts 93 
with a manganese(II)-based MIL solvent support through hydrophobic interactions, π-π stacking, 94 
and fluorophilic interactions.[29,34] Recent efforts have focused on improving loading of the 95 
ITO-DNA duplex to the MIL support though the use of disubstituted ion-tagged oligonucleotides 96 
(DTOs), which contain two imidazolium headgroups capable of interacting with the MIL 97 
through hydrophobic interactions.[34] Another recent study developed a dispersive ITO-MIL 98 
method that drastically decreased the sample preparation time by dispersing the MIL using a 99 
vortex and incorporating DNA-enriched MIL into the qPCR buffer, allowing for a 19-fold 100 
enrichment of target DNA.[33]  101 
Despite significantly higher loading efficiencies asociated with the DTO, both the ITO 102 
and DTO probes extract similar amounts of DNA under optimized extraction conditions.[34] 103 
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However, it still remains unclear as to whether the DTO and ITO probes exhibit similar DNA 104 
extraction performances from complex matrices such as plasma and whole blood. In addition, 105 
there has been little optimization of the desorption step in the ITO/DTO-MIL procedure, as 106 
previous methods have relied on either a time-consuming 10 min desorption step at 90 °C or 107 
desorption of DNA during qPCR amplification, which is restricted by the temperature program 108 
and buffer conditions required for PCR.[29,33–35] This study examines the sequence-specific 109 
extraction of KRAS DNA from 10-fold diluted plasma, 2-fold diluted plasma, and 10-fold diluted 110 
whole blood using both ITO and DTO probes. In addition, the desorption time and ionic strength 111 
of the desorption solution were optimized to ensure maximum recovery of target DNA from the 112 
MIL. The ITO/DTO-MIL method was found to be selective when performing extractions from 113 
saline (154 mM NaCl), 10-fold diluted plasma, 2-fold diluted plasma, and 10-fold diluted blood. 114 
However, the DTO probes were significantly more advantageous in extractions from 2-fold 115 
diluted plasma and 10-fold diluted whole blood whereas the ITO probes extracted more DNA 116 
from saline compared to DTOs. These results suggest that the DTO-MIL procedure is highly 117 
versatile and capable of selectively preconcentratig femtomolar levels of target DNA from very 118 
complex samples that contain high amounts of protein and background DNA whereas the ITO 119 
probe excels when performing extraction from samples with elevated ionic strength. 120 
2. Methods and Materials 121 
2.1 Materials and Reagents 122 
Ammonium hydroxide (28-30% solution in water), 1,1,5 5,5-hexafluoroacetylacetone 123 
(99%), 1-phenyl-4,4,4-trifluoro-1,3-butanedione (99%), and trioctylamine (97%) were purchased 124 
from Acros Organics (Morris Plains, NJ, USA). Mangaese(II) chloride tetrahydrate (98.0-125 
101.0%) was purchased from Alfa Aesar (Ward Hill, MA, USA). Anhydrous diethyl ether 126 
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(99.0%) was purchased from Avantor Performance Materials Inc. (Center Valley, PA, USA). 127 
Trihexyl(tetradecyl)phosphonium chloride (97.7%) was purchased from Strem Chemicals 128 
(Newburyport, MA, USA). Ammonium persulfate (APS) (≥98.0%), allyl bromide, 129 
ethylenediaminetetraacetic acid (EDTA) (99.4-100.06%), 1-bromooctane (99%), 130 
benzylimidazole (99%), triethylamine (≥99.5%), sodium octylsulfate ([OS-]) (>95%), Tween 20, 131 
LC-MS grade acetonitrile (ACN) (≥99.9%), lyophilized plasma from human (4% trisodium 132 
citrate), potassium hexafluorophosphate ([PF6
-]) (≥99%), and magnesium chloride hexahydrate 133 
(99.0-102.0%)  were purchased from Sigma-Aldrich (St. Louis, MO, USA). SYBR Green I 134 
(10,000x) was purchased from Life Technologies (Carlsb d, CA, USA). Proteinase K was 135 
purchased from New England Biolabs (Ipswich, MA, USA). Tris(hydroxymethyl)aminomethane 136 
(Tris) hydrochloride (HCl), urea (>99%) and tris(2-carboxyethyl)phosphine (TCEP) (>98%) 137 
were purchased from P212121 (Ypsilanti, MI, USA). SsoAdvanced Universal SYBR Green 138 
Supermix (2x), 40% acrylamide, bis-acrylamide soluti n 29:1, tetramethylethylenediamine 139 
(TEMED), and KRAS, a human PrimePCRTM SYBR green assay (120 base pair amplicon), were 140 
purchased from Bio-Rad Laboratories (Hercules, CA, USA). Cyclic disulfide-modified, thiol-141 
modified, biotinylated, and unmodified oligonucleotides were purchased from Integrated DNA 142 
Technologies (Coralville, IA, USA). PCR caps, tube strips, sodium chloride, fresh human whole 143 
blood, and Dynabeads Steptavidin M-270 magnetic beads were purchased from Thermo Fisher 144 
Scientific (Waltham, MA, USA). Neodymium rod (0.66 T) and cylinder magnets (0.9 T) were 145 
purchased from K&J Magnetics (Pipersville, PA, USA). Deionized water (18.2 MΩ cm), 146 
obtained from a Milli-Q water purification system, was used to prepare all aqueous solutions 147 
(Millipore, Bedford, MA, USA).  148 
2.2 Synthesis and characterization of DTOs, ITOs, and MILs 149 
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The trihexyl(tetradecyl)phosphonium ([P6,6,6,14
+]) 150 
tris(hexafluoroacetylaceto)manganate(II) ([Mn(hfacac)3
-]), [P6,6,6,14
+] 151 
tris(phenyltrifluoroacetylacetomanganate(II) ([Mn(Phtfacac)3
-]), trioctylbenzylammonium 152 
([N8,8,8,Bz
+]) [Mn(hfacac)3
-], and [N8,8,8,Bz
+] 153 
bis(hexafluoroacetylaceto)phenyltrifluoroacetylacetomanganate(II) ([Mn(hfacac)2(Phtfacac)
-]) 154 
MILs were synthesized and characterized as previously reported.[33,36–38] MIL structures are 155 
shown in Figure 1. When not in use, all four MILs were stored at room temperature in a 156 
desiccator.  157 
The 1-allyl-3-octylimidazolium bromide ([AOIM+][Br -]), 1-allyl-3-decylimidazolium 158 
bromide ([ADIM+][Br -]), and 1-allyl-3-benzyllimidazolium bromide ([ABzIM+][Br -]) ILs were 159 
synthesized as previously reported.[29] In addition, all ITOs and DTOs were also synthesized as 160 
previously reported.[29,34] Briefly, 4 nmol of the thiol-modified oligonucleotide or 2 nmol of 161 
the cyclic disulfide-modified oligonucleotide was reduced using 40 nmol of TCEP. 162 
Subsequently, 400 nmol of either the [AOIM+][Br -], [ADIM +][Br -], or [ABzIM+][Br -] salt (30% 163 
v/v ACN) was reacted with the reduced oligonucleotide under nitrogen (N2) at 365 nm UV light 164 
for approximately 120 min. A NotePal X-slim Cooler Master (New Taipei City, Taiwan) was 165 
used to cool the reaction to prevent solvent evaporation. The product was isolated using 166 
polyacrylamide gel electrophoresis (PAGE) and recovred by crushing the gel and eluting with 167 
water. 168 
 ITOs and DTOs were characterized using reversed-phase ion-pair liquid chromatography 169 
coupled to time-of-flight mass spectrometry (TOF-MS) on an Agilent 1260 Infinity high 170 
performance liquid chromatograph (HPLC) with a diode array detector coupled to an Agilent 171 
6230B TOF mass spectrometer with an electrospray source. ITOs and DTOs were separated on a 172 
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50 mm × 2.1 mm i.d. × 1.8 µm particle size Zorbax Extend C18 column purchased from Agilent 173 
Technologies (Santa Clara, CA, USA). Mobile phase A contained 5 mM triethylammonium 174 
acetate (pH 7.4) and mobile phase B was ACN. The column was equilibrated for 20 min at 0.2 175 
mL min−1 at 5% B. Gradient separation of ITO products was performed using the following 176 
program: 5% B from 0 to 5 min, increased from 5% to 19.4% B from 5 to 17 min, increased 19.4 177 
to 35% B from 17 to 18 min, held at 35% B from 18 to 20 min, increased 35% B to 100% B 178 
from 20 to 30 min, and held at 100% B from 30 to 33 min. After each separation, the column 179 
was equilibrated at 5% B for 7 min prior to subsequent injections. The LC eluent was diverted to 180 
waste for the first 8 min to prevent non-volatile imidazolium salts and urea from entering the 181 
mass spectrometer. Nebulizing gas was set to 35 psi, and the drying gas (N2) flow rate was 9 L 182 
min−1 at 350 °C using a capillary voltage of 4000 V. Spectra were acquired from 100 to 3000 183 
m/z with a scan rate of 1 spectrum sec−1. ITO and DTO structures are shown in Figure 2. The184 
extracted ion chromatograms and mass spectra of the [AOIM +]2-KRAS 2[Br
-], [ADIM +]2-KRAS 185 
2[Br-], and [ABzIM+]2-KRAS 2[Br
-] DTOs are shown in Figure S1 (supplementary information). 186 
2.3 Loading efficiency of ITOs and DTOs to the hydrophobic MIL 187 
The stability of the interaction between the ITO/DTO-DNA duplex and MIL was 188 
determined by anion exchange chromatography using an Agilent 1260 HPLC with variable 189 
wavelength detection. First, 2 ppm of the DNA extraction probe was hybridized with 2 ppm of 190 
its complementary sequence in 25 mM NaCl by heating at 90 °C for 5 min then cooling to 4 °C 191 
for 5 min. The ITO/DTO-DNA duplex was incubated for10 min at room temperature with 1 µL 192 
of MIL. After this, 20 µL of the aqueous solution was injected onto a 35 mm × 4.6 mm i.d. × 2.5 193 
µm TSKgel DEAE-NPR anion exchange column with a 5 mm × 4.6 mm i.d. × 5 µm TSKgel 194 
DEAE-NPR guard column from Tosoh Bioscience (King of Prussia, PA). Mobile phase A 195 
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consisted of 20 mM Tris-HCl (pH 8) and mobile phase B was 20 mM Tris-HCl and 1 M NaCl 196 
(pH 8). The column was equilibrated with mobile phase A at 0.5 mL min -1 for 20 min prior to 197 
injection. Gradient elution was performed with the following program: increased from 0 to 50 % 198 
B from 0  to 10 min, increased to 100 % B from 10 min to 15 min, held at 100 % B from 15 min 199 
to 20 min, decreased to 0 % B from 20 min to 22 min, held at 0 % B from 22 min to 30 min. 200 
2.4 qPCR conditions 201 
Quantitative PCR (qPCR) was achieved using 1x Sso Supermix and 1x PrimePCR assay 202 
mix with a final volume of 20 µL. Addition of 0.3 µL [P6,6,6,14
+][Mn(hfacac)3
-] MIL to the qPCR 203 
buffer required 1x Sso Supermix and 1x PrimePCR assay mix, 4 mM EDTA, and an additional 204 
1x SYBR Green I to relieve inhibition caused by theMIL. Direct MIL-qPCR amplification using 205 
the [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL required 1x Sso Supermix and 1x PrimePCR assay mix, 206 
additional 6.25 mM MgCl2, 4 mM EDTA, and an additional 0.4x SYBR Green I. A 20 µL qPCR 207 
containing 0.3 µL of the [N8,8,8,Bz
+][Mn(hfacac)3(Phtfacac)
-] MIL required 1x Sso Supermix and 208 
1x PrimePCR assay mix, an additional 2.5 mM MgCl2, 2 mM EDTA, and an additional 1x 209 
SYBR Green I. Amplification was achieved on a Bio-rad CFX 96 qPCR using the following 210 
cycling protocol: 2 min initial denaturation at 95 °C followed by 40 cycles comprised of a 5 s 211 
denaturation step at 95 °C, a 30 s annealing step at 60 °C, and an optical detection step. 212 
Quantification cycles (Cq) were determined using the Bio-Rad CFX Maestro software. A 213 
standard curve was constructed for the KRAS template, as shown in Figure S2, and used to 214 
determine the amount of target extracted using the ITO-MIL procedure. Enrichment factors (Ef) 215 
were determined using equation 1 where CMIL  is the amount of DNA extracted by 0.3 µL of MIL 216 
and Cstd is the amount of DNA present in a 0.3 µL of the soluti n prior to the extraction. 217 
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                                                     E = 	

	

                                                   Equation 1       218 
2.5 Extraction of target DNA  219 
Static extractions were used to selectively extract high concentrations of target DNA 220 
using previously published methods, with slight modifications.[29,34] Briefly, 7.2 × 107 copies 221 
µL-1 (112 pM) of target DNA was hybridized to either 3.6×108 copies µL-1 of DTO or 7.2 × 108 222 
copies µL-1 of ITO by heating the solution at 90 °C for 5 min to denature double-stranded DNA 223 
followed by cooling to 4 °C for 5 min. After hybridization, 1 µL of MIL was added to the sample 224 
for 10 min at room temperature. Subsequently, the MIL was washed with water to remove non-225 
specifically adsorbed DNA and inhibitors from the surface of the MIL. Target DNA was 226 
subsequently desorbed in 50 µL of 25-400 mM NaCl at 90 °C for 1-10 min.  227 
Dispersive extractions were achieved using the previously optimized method with a DTO 228 
probe to target ratio of 5:1 and ITO probe to target atio of 10:1.[33,34] Briefly, 4, 6, or 8 µL of 229 
the [N8,8,8,Bz
+][Mn(Phtfacac)(hfacac)2
-], [N8,8,8,Bz
+][Mn(hfacac)3
-], and [P6,6,6,14
+][Mn(hfacac)3
-] 230 
MILs,  respectively, were dispersed in a 1 mL soluti n containing 2×104 copies µL-1 (33 fM) of 231 
KRAS DNA using a vortex (Barnstead International, Dubuque, IA). After a 1 or 3 min 232 
dispersion, the MIL was collected using a 0.66 T rod magnet, and 0.3 µL of the recovered MIL 233 
was added to qPCR buffer.  234 
Extractions using the M-270 streptavidin-coated magnetic beads were performed as 235 
recommended by the manufacturer. Prior to every extraction, 10 µg of magnetic beads were 236 
washed three times with 5 mM Tris-HCl, 0.5 mM EDTA, and 1 M NaCl (pH 7.5). All DNA 237 
extractions consisted of 10:1 biotinylated probe to target ratio in 25 mM NaCl. The sample was 238 
initially heated at 90 °C for 5 min then cooled to 4 °C for 5 min to anneal the biotinylated probe 239 
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to the target. Samples were subsequently agitated at 60 rpm or 250 rpm for extractions of 240 
7.2×107 and 2×104 copies µL-1 KRAS, respectively, on an orbital shaker for 10 min to disperse 241 
the beads and minimize sedimentation. The beads were collected using a 0.9 T magnet and 242 
washed three times with a solution consisting of 5 mM Tris-HCl, 0.5 mM EDTA, and 1 M NaCl 243 
(pH 7.5). DNA was desorbed from the beads in 20 µL water by heating to 90 °C for 10 min. 244 
Target KRAS DNA was spiked into plasma and whole blood matrices. Plasma samples 245 
were diluted using water whereas whole blood was diluted in saline in order to prevent settling of 246 
cellular debris prior to the extraction. The amount of total genomic DNA in whole blood was 247 
determined using the QIAmp DNA mini-prep kit following procedures suggested by the 248 
manufacturer.  249 
2.6 Statistical analysis 250 
The Student -test was used to determine whether the DTO or ITO probe was extracting 251 
significantly more DNA. Selectivity was also determined using the Student t-test by comparing 252 
the extractions with and without a DNA extraction probe. Probability values (p-values) were 253 
determined from the t-test results, and a significance level of 0.05 was chosen. Therefore, if the 254 
p-value is less than 0.05, the two data sets were considered statistically different. 255 
3. Results and Discussion 256 
3.1 Synthesis of novel DTO probes 257 
Since ITO and DTO probes can interact with the MIL through hydrophobic interactions, 258 
incorporation of longer alkyl chain substituents within the probe would be expected to improve 259 
the amount of DNA loaded to the MIL. Previously, an [AOIM +][Br -] ITO specific to a 261 bp 260 
DNA sequence was capable of achieving a modest loading efficiency of 48±4% with the 261 
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[P6,6,6,14
+][Mn(hfacac)3
-] MIL; however, increasing the alkyl chain by just two carbons 262 
significantly improved the loading efficiency to 75±5%.[34] In this study, a novel DTO 263 
containing two decyl-imidazolium headgroups was synthesized to further improve the loading 264 
efficiency of the probe to the MIL. Attempts to synthesize a DTO with alkyl chains longer than 265 
ten carbon atoms resulted in the allylimidazolium cation reacting with only one of the two thiol 266 
groups, as shown using MS (Figure S3). The incomplete reaction maybe due to the imidazolium 267 
salt exhibiting surfactant-like properties and forming aggregates with the cyclic disulfide-268 
modified oligonucleotide.[39]  269 
In order to identify the optimum ITO and DTO for loading target DNA to the MIL, the 270 
loading efficiency of four ITOs and seven DTOs to three hydrophobic MILs was studied, as 271 
shown in Figure 3. The [AOIM+]-KRAS [PF6
-] ITO (56.94±1.61%) provided the highest loading 272 
efficiency to the [P6,6,6,14
+][Mn(hfacac)3
-] MIL whereas there was no significant difference in 273 
loading efficiencies observed for the [ADIM+]2-KRAS 2[Br
-] (87.65±2.21%) and [ADIM+]2-274 
KRAS 2[OS-] DTOs (83.56±5.06%).  For the [N8.8.8.Bz
+][Mn(hfacac)3
-] MIL, the [ABzIM+]-KRAS 275 
[Br-] ITO (65.94±9.55%) produced the highest loading and there was no significant difference in 276 
loading for the [ADIM+]2-KRAS [Br
-] (86.28±4.39%), [ADIM+]2-KRAS [PF6
-] (94.28±2.47%), 277 
and [ABzIM+]2-KRAS [Br
-] DTOs (89.2±2.68%). Based on the Student t-test, there was no 278 
significant advantage in loading of the DNA extraction probe to the 279 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
 -] MIL using either the [AOIM+]2-KRAS 2[Br
-] (56.91±7.67%) 280 
or [ADIM +]2-KRAS 2[Br
-] DTOs (60.83±3.95%). Among the ITOs and DTOs examined, the 281 
[ABzIM +]-KRAS [Br-] ITO (53.69±2.27%) produced the highest loading efficiency using the 282 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
 -] MIL.  283 
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It was previously reported that ITOs containing the [OS-] anion exhibited superior 284 
loading to the MIL solvent compared to [Br-], bis[(trifluoromethyl)sulfonyl]imide, or 285 
perfluorobutanesulfonate anions suggesting that the anion plays an important role in facilitating 286 
the capture of the ITO by the MIL.[34] Therefore, rplacing the [Br-] anion within the DTO 287 
structure with the amphiphilic [OS-] anion should improve the loading of the DTO probe to the 288 
MIL. However, introducing the [OS-] anion to the DTO did not significantly improve the loading 289 
efficiency. Utilizing the [PF6
-] anion to facilitate fluorophilic interactions between the DTO and 290 
MIL also did not improve the loading of the probe to the MIL. These results suggest that the 291 
anion component of the DTO plays a less important role in facilitating interactions between the 292 
DTO and the MIL compared to the ITO probe. Interestingly, the [ABzIM+]2-KRAS 2[Br
-] DTO 293 
showed relatively low loading to the [P6,6,6,14
+][Mn(Phtfacac)3
-] (17.21±1.70%) and 294 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] (14.23±0.91%) MILs. The [ABzIM+]2-KRAS 2[Br
-] DTO was 295 
effective at loading to the [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL and the [ABzIM+]-KRAS [Br-] ITO 296 
exhibited the highest loading efficiencies for the [N8,8,8,Bz
+][Mn(hfacac)3
-] and 297 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs. These results suggest that exploiting π-π stacking 298 
interactions with the DTOs is effective when the aromatic moieties are only in the cation. 299 
3.2 Distinguishing SNPs from target DNA using ITO and DTO probes 300 
In blood plasma samples, especially with late stage cancer patients, there are large 301 
amounts of non-target background DNA fragments (ranging from 0-100 pM) that can potentially 302 
be co-extracted.[27] In addition, ctDNA fragments are prone to SNPs and require great care to 303 
ensure that only the desired sequence is detected. To evaluate the effect interfering DNA has on 304 
the annealing of target DNA to the extraction probe, extractions from samples containing 305 
7.2×107 copies µL-1 of 20 nt complement, 1 nt mismatch, or 2 nt mismatch fragments (i.e., 1:1 306 
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ratio with target DNA) were performed using the [P6,6,6,14
+][Mn(hfacac)3
-] MIL and streptavidin 307 
coated magnetic beads. Without interfering fragments present, the [ADIM+]2-KRAS 2[Br
-] and 308 
[ADIM +]2-KRAS 2[OS
-] DTOs extracted the most DNA (target capture Cq of 21.13±0.30 and 309 
21.28±0.05, respectively). The addition of a 20 nt complementary sequence to the sample 310 
resulted in a higher target capture Cq indicating that less of the 120 bp target was extracted, as 311 
shown in Figure S4. These results suggest that the complementary fragment competed with the 312 
120 bp amplicon for the probe causing lower DNA recoveries. The addition of either 1 or 2 nt 313 
mismatch fragments to the sample solution did not significantly increase the target capture Cq 314 
when using the [AOIM+]2-KRAS [PF6
-], [ABzIM +]-KRAS [Br-], [AOIM +]2-KRAS 2[Br
-], 315 
[AOIM +]2-KRAS 2[OS
-], [ADIM +]2-KRAS 2[Br
-], and [ADIM+]2-KRAS 2[OS
-] extraction probes. 316 
This suggests that the 1 nt and 2 nt mismatch fragments are not interfering with the annealing of 317 
target DNA to the probe.  318 
The streptavidin-coated magnetic beads also experienced an increase in target capture Cq 319 
when performing extractions in the presence of a 20 nt complement. However, the target capture 320 
Cq also increased when performing extractions with 1 nt and 2 nt mismatch fragments spiked in 321 
the sample. This increase suggests that the biotinyla ed probe is annealing to the 1 and 2 nt 322 
mismatch fragment and, therefore, reducing the amount f target DNA that can be captured.  323 
3.3 Optimization of the desorption step 324 
Although there has been a significant amount of work performed to improve the loading 325 
efficiency of the ITO-DNA duplex to the MIL, few studies have evaluated the desorption step. 326 
Therefore, the desorption time and ionic strength of the desorption solution were optimized to 327 
improve the recovery of DNA from the [P6,6,6,14
+][Mn(hfacac)3
-], [N8,8,8,Bz
+][Mn(hfacac)3
-], and 328 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs. As shown in Figure S5, an optimum desorption time 329 
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of 4 min was achieved for the [P6,6,6,14
+][Mn(hfacac)3
-] and [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] 330 
MILs, and an optimum desorption time of 4 min and 8 min was achieved for the 331 
[N8,8,8,Bz
+][Mn(hfacac)3
-] MIL with the ITO and DTO probe, respectively. Less DNA was 332 
recovered after longer desorption times likely due to DNA adsorbing to the polypropylene 333 
tube.[40] Therefore, 0.05% Tween 20 was added to the desorption solution in an effort to 334 
minimize adsorption. A 4 min desorption time was chosen as optimum due to the high amount of 335 
DNA recovered using all three MILs, while still maintaining a short desorption time. In addition, 336 
the presence of NaCl greatly promoted the desorption of DNA, as shown in Figure S6. The 337 
optimum concentration of NaCl was 100 mM for the [P6,6,6,14
+][Mn(hfacac)3
-] MIL, 200 mM for 338 
the [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL, and 50 mM for the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL. 339 
There was no significant difference between the amount f DNA detected when ITO and DTO 340 
were used to extract DNA if desorbing at higher ionic strength. This suggests that electrostatic 341 
interactions between the ITO or DTO and the MIL may also play a role in the capture of the 342 
ITO/DTO-DNA duplex. 343 
 Recent studies have exploited the elevated temperatur s required for PCR to desorb 344 
DNA from the MIL solvent during the reaction.[32,3341] Adding DNA-enriched MIL to the 345 
PCR buffer is highly beneficial as it reduces the number of sample handling steps, allowing for 346 
higher sample throughput and minimizes the possibility of contamination. Interestingly, despite 347 
similar target capture Cqs being achieved with the DTO and ITO probes using 25 to 400 mM 348 
NaCl as a desorption solution, lower target capture Cqs and higher Ef were achieved using the 349 
ITOs when desorbing in 1x Sso Supermix, as shown in Figures S7 and S8.  350 
3.4 Sequence-specific DNA extractions from complex matrices 351 
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Several reported sequence-specific DNA extraction pr cedures isolate total DNA prior to 352 
an extraction due to the complexity of the sample matrix.[20,42] However, this is often very time 353 
consuming, and an ideal sequence-specific DNA extraction should be capable of selectively 354 
extracting DNA from complex sample matrices. Previously, the ITO-MIL procedure has been 355 
applied towards bacterial cell lysate (1.53×108 E. coli cells),[29] 10-fold diluted plasma,[33] and 356 
plant cell lysate.[35] However, it has been unclear if either the ITO or DTO probe can extract 357 
more DNA from complex matrices. When comparing the extraction of KRAS from 10-fold 358 
diluted plasma using the DTO or ITO probe, more DNA was detected using the [AOIM+]-KRAS 359 
[PF6
-] ITO with the [P6,6,6,14
+][Mn(hfacac)3
-] MIL and the [ADIM+]2-KRAS 2[Br
-] DTO probe 360 
with the [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL, as shown in Figure 4. There was no significant difference 361 
observed between the [ADIM+]2-KRAS 2[Br
-] DTO and [ABzIM+]-KRAS [Br-] ITO probes with 362 
the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL in 10-fold diluted plasma. At femtomolar 363 
concentration-levels of target DNA, similar Ef was achieved using either the [ADIM
+]2-KRAS 364 
2[Br-] DTO or [ABzIM+]-KRAS [Br-] ITO probes with the [N8,8,8,Bz
+][Mn(hfacac)3
-] or 365 
[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs, as shown in Figure 5. The [AOIM+]-KRAS [PF6
-] ITO 366 
was capable of preconcentrating significantly more DNA from 10-fold diluted plasma compared 367 
to the [ADIM+]2-KRAS 2[Br
-] DTO probe with the [P6,6,6,14
+][Mn(hfacac)3
-] MIL. 368 
Selective preconcentration of 2×102 and 2×103 copies µL-1 (0.33 and 3.3 fM, 369 
respectively) of KRAS from 10-fold diluted plasma was achieved using the ITO and DTO probes, 370 
as shown in Figure S9. However, based on the Student t-t st there was no significant difference 371 
in Ef using the DTO or ITO at these concentrations
 suggesting that both probes function similarly 372 
at enriching low concentrations of DNA. When performing extractions of 2×102 copies µL-1 of 373 
KRAS from 10-fold diluted plasma, the [N8,8,8,Bz
+][Mn(hfacac)3
-] and 374 
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[N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs exhibited slight preconcentration of DNA suggesting 375 
that the selectivity of the ITO/DTO-MIL method worsens as the concentration of target DNA 376 
decreases. Interestingly, extractions of either 7.2×107 or 2×104 copies µL-1 KRAS DNA from 10-377 
fold diluted plasma using streptavidin-coated magnetic beads were not selective. It is possible 378 
that free biotin naturally found in plasma blocks binding sites on the beads or that the 379 
biotinylated probe is binding to plasma proteins.[43– 5]  380 
 Previous studies have shown that imidazolium ILs that contain longer alkyl chain 381 
substituents (i.e., octyl chain length) interact more with proteins.[46] In the case of the 382 
ITO/DTO-procedure, the longer alkyl chains are used to improve loading of the probe-DNA 383 
duplex to the hydrophobic MIL; however, it is unclear if certain ITOs or DTOs strongly interact 384 
with plasma proteins instead of the MIL. Therefore, extractions from 10-fold diluted plasma 385 
were performed using the [ADIM+]2-KRAS 2[Br
-] and [ABzIM+]2-KRAS 2[Br
-] DTOs with the 386 
[N8,8,8,Bz
+][Mn(hfacac)3
-] MIL and the [ADIM+]2-KRAS 2[Br
-] and [ADIM+]2-KRAS 2[OS
-] 387 
DTOs with the [P6,6,6,14
+][Mn(hfacac)3
-] MIL. These DTOs were chosen because they exhibited 388 
similar loading efficiencies and, therefore, should extract similar amounts of DNA. As shown as 389 
Figure S10, the target capture Cqs associated with the extractions using the [ADIM+]2-KRAS 390 
2[Br-] and [ABzIM+]2-KRAS 2[Br
-] DTOs with the [N8,8,8,Bz
+][Mn(hfacac)3
-] and the [ADIM+]2-391 
KRAS 2[Br-] and [ADIM+]2-KRAS 2[OS
-] DTOs with the [P6,6,6,14
+][Mn(hfacac)3
-] MIL were 392 
within error. The target capture Cqs suggest that te different DTO probes suffer from similar 393 
matrix effects due to the plasma components.  394 
Diluting the sample matrix can be beneficial as it decreases the concentration of PCR 395 
inhibitors and reduces the amount of protein aggregates. However, diluting the sample matrix 396 
also decreases the amount of DNA making it more challenging to detect low abundance 397 
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mutations. Therefore, ITO/DTO-MIL extractions from 2-fold diluted plasma were investigated. 398 
Selective extractions from 2-fold diluted plasma were achieved for all three MILs, as shown in 399 
Figure S11. However, extractions using the DTO probe produced lower target capture Cqs 400 
compared to extractions using the ITO probes, possibly due to stronger interactions between the 401 
probe and hydrophobic MIL. The streptavidin-coated magnetic beads were capable of selective 402 
extraction in 2-fold diluted plasma whereas previously the extractions with and without the 403 
biotinylated probe in 10-fold diluted plasma were within error of one another. This may be 404 
linked to the significant amount of protein aggregation that occurs during the annealing step with 405 
2-fold diluted plasma. Protein precipitation could limit the amount of biotinylated probe that 406 
interacts with soluble plasma proteins and allow for higher DNA recoveries.[43]  407 
In most ctDNA sample preparation methods, ctDNA is extracted from plasma instead of 408 
whole blood due to the high probability of contaminat g the sample with genomic DNA from 409 
circulating cells.[47,48] To ensure that plasma is cell-free, a lengthy double centrifugation step is 410 
required.[47,48] In addition, the process of generating plasma from blood removes circulating 411 
cell surface-bound DNA from analysis, which can aidcancer diagnosis and monitoring.[49] 412 
Therefore, the ITO/DTO-MIL method was applied towards the extraction of KRAS from 10-fold 413 
diluted whole blood to examine if selective extraction could be achieved. When performing 414 
ITO/DTO-MIL extractions from 10-fold diluted blood at picomolar levels of DNA, selective 415 
extraction was achieved using the [P6,6,6,14
+][Mn(hfacac)3
-] and [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs, 416 
as shown in Figure 6. However, selective extraction c uld not be achieved using the [ABzIM+]-417 
KRAS [Br-] ITO with the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL or the magnetic beads. 418 
Selective extraction using the magnetic beads could n y be achieved when diluting the blood 419 
40-fold, as shown in Figure S12. It was also possible to achieve selective extraction using the 420 
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streptavidin-coated magnetic beads by proteinase K treatment at 56 °C for 15 min prior to 421 
annealing the probe to target DNA, as shown in Figure 7. In this procedure, the sample was also 422 
filtered to remove cellular debris and precipitated proteins before the magnetic beads were 423 
added. It was found that the [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL was unable to selectively 424 
extract target DNA due to the saline solution used to ilute whole blood, as shown in Figure S13. 425 
Extractions from saline using the [P6,6,6,14
+][Mn(hfacac)3
-] or [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs 426 
resulted in higher target capture Cqs when compared to extractions performed from pure water, 427 
possibly due to the higher ionic strength increasing the melting temperature of the target DNA. 428 
The ITO probes were capable of extracting more DNA from saline compared to the DTO, but all 429 
extractions from saline with the [P6,6,6,14
+][Mn(hfacac)3
-] or [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs were 430 
selective.  431 
When performing extractions from clinically-relevant concentrations of ctDNA, selective 432 
extraction using either the ITO or DTO probes was achieved with the [P6,6,6,14
+][Mn(hfacac)3
-] 433 
and [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs, as shown in Figures 7. However, the DTO preconcentrated 434 
significantly more DNA compared to the ITO in whole blood matrices possibly due to stronger 435 
interactions between the probe and MIL during the extraction and washing steps. When 436 
performing extractions at 2×102 and 2×103 copies µL-1 (mutation abundance of 0.009% and 437 
0.09%, respectively) with the [P6,6,6,14
+][Mn(hfacac)3
-]  and [N8,8,8,Bz
+][Mn(hfacac)3
-] MILs, 438 
selective preconcentration of target DNA could still be achieved using the [ADIM+]2-KRAS 2[Br
-
439 
] DTO, as shown in Figure S14. However, extractions f 2×102 copies µL-1 KRAS from 10-fold 440 
diluted blood resulted in slight preconcentration when the DTO probe was not present, again 441 
suggesting that the DTO-MIL method is prone to co-extraction under conditions of low target 442 
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DNA concentration. This effect could possibly be limited by designing the MIL to further limit 443 
DNA extraction. 444 
4. Conclusions 445 
  The ability of the ITO/DTO-MIL method to selectively extract DNA from 2-fold diluted 446 
plasma, 10-fold diluted plasma, and 10-fold diluted whole blood has been demonstrated. The 447 
desorption time and ionic strength of the desorption s lution were optimized to ensure the 448 
maximum amount of DNA was desorbed from the MIL in a short amount of time (i.e., 4 min), 449 
with higher ionic strength significantly facilitating the desorption of DNA from the hydrophobic 450 
MIL. ITO probes were successful at extracting more DNA in saline compared to DTO probes, 451 
but DTO probes outperformed ITOs by extracting more DNA from complex biological matrices, 452 
including 2-fold diluted plasma and 10-fold diluted blood. However, there was no significant 453 
difference in enrichment factor when performing extrac ions from 10-fold diluted plasma with 454 
either the ITO or DTO. In comparison, commercially-available streptavidin-coated magnetic 455 
beads only exhibited selectivity in 2-fold diluted plasma and 40-fold diluted whole blood without 456 
labor-intensive sample clean-up steps. The DTO-MIL method represents a simple two-step 457 
extraction procedure to selectively preconcentrate low concentrations of DNA from increasingly 458 
complex matrices, suggesting that this method has te potential to be highly valuable in the field 459 
of ctDNA detection and analysis.  460 
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 618 
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 620 
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 623 
Figure Legends: 624 
Fig. 1 Chemical structures of the (1) [P6,6,6,14
+][Mn(hfacac)3
-], (2) [P6,6,6,14
+][Mn(Phtfacac)3
-], (3) 625 
[N8,8,8,Bz
+][Mn(hfacac)3
-], and (4) [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs examined in this 626 
study. 627 
Fig. 2 Chemical structures of the imidazolium-based ion tags associated with the (A-B) ITOs and 628 
(C-E) DTOs examined in this study. 629 
Fig. 3 Loading efficiencies of the ITO and DTO probes to the (a) [P6,6,6,14
+][Mn(hfacac)3
-], (b) 630 
[N8,8,8,Bz
+][Mn(hfacac)3
-], and (c) [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MILs. ITO or DTO 631 
concentration: 2 ng µL-1; KRAS complement: 2 ng µL-1; NaCl concentration: 25 mM; sample 632 
volume: 60 µL; MIL volume: 1 µL; extraction time: 10 min. 633 
Fig. 4 Target capture Cq associated with the static extraction using the (blue) [ADIM+]2-KRAS 634 
2[Br-] DTO, (green) highest loading ITO, (orange) biotinylated probe, and (grey) without a DNA 635 
extraction probe from 10-fold diluted plasma. ITO/DTO-MIL method: KRAS template 636 
concentration: 7.2×107 copies µL-1, amount of [ADIM+]-KRAS 2[Br-] DTO relative to DNA: 5:1, 637 
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amount of [AOIM+]-KRAS [PF6
-] ITO relative to DNA: 10:1, sample volume: 50 µL, MIL 638 
volume: 1 µL; extraction time: 10 min, desorption time: 4 min, desorption volume: 50 µL. 639 
Dynabeads M-270 Steptavidin magnetic beads conditios: KRAS template concentration: 2×104 640 
copies µL-1, concentration of biotinylated probe: 332 fM, NaCl concentration: 25 mM, extraction 641 
time: 10 min; agitation rate: 250 rpm; desorption time: 10 min; desorption volume: 50 µL.  642 
 643 
Fig. 5 Enrichment factors from the dispersive extraction using the (blue) [ADIM+]2-KRAS 2[Br
-] 644 
DTO, (green) highest loading ITO, (orange) biotinylated probe, and (grey) without a DNA 645 
extraction probe from 10-fold diluted plasma. [P6,6,6,14+] [Mn(hfacac)3-] MIL conditions: amount 646 
of [ADIM +]-KRAS 2[Br-] DTO relative to DNA: 5:1, amount of [AOIM+]-KRAS [PF6
-] ITO 647 
relative to DNA: 10:1, NaCl concentration: 25 mM, sample volume: 1.0 mL, extraction time: 3 648 
min. [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL conditions: amount of [ADIM+]-KRAS 2[Br-] DTO relative to 649 
DNA: 5:1, amount of [ABzIM+]-KRAS [Br-]  relative to DNA: 10:1, NaCl concentration: 25 650 
mM, sample volume: 1.0 mL, extraction time: 1 min. [N8,8,8,Bz
+][Mn(hfacac)2(Phtfacac)
-] MIL 651 
conditions: amount of [ADIM+]-KRAS 2[Br-] DTO relative to DNA: 5:1, amount of [ABzIM+]-652 
KRAS [Br-]  relative to DNA: 10:1, NaCl concentration: 25 mM, sample volume: 1.0 mL, 653 
extraction time: 1 min. Dynabeads M-270 Steptavidin magnetic beads conditions: concentration 654 
of biotinylated probe: 332 fM; extraction time: 10 min; agitation rate: 250 rpm; desorption time: 655 
10 min; desorption volume: 20 µL. 656 
 657 
Fig. 6 Target capture Cq obtained from static extraction usi g the (blue) [ADIM+]2-KRAS 2[Br
-] 658 
DTO, (green) highest loading ITO, and (orange) biotinylated probe compared to extractions 659 
(grey) without a DNA extraction probe from 10-fold diluted blood. ITO/DTO-MIL method: 660 
KRAS template concentration: 7.2×107 copies µL-1, amount of [ADIM+]-KRAS 2[Br-] DTO 661 
relative to DNA: 5:1, amount of [AOIM+]-KRAS [PF6
-] ITO relative to DNA: 10:1, sample 662 
volume: 50 µL, MIL volume: 1 µL; extraction time: 10 min, desorption time: 4 min, desorption 663 
volume: 50 µL. Dynabeads M-270 Steptavidin magnetic beads conditi s: KRAS template 664 
concentration: 7.2×107 copies µL-1, concentration of biotinylated probe: 7.2×108 copies µL-1; 665 
extraction time: 10 min; agitation rate: 250 rpm; desorption time: 10 min; desorption volume: 50 666 
µL.  667 
 668 
Fig. 7 Enrichment factor produced from the dispersive extraction of KRAS target using the (blue) 669 
[ADIM +]2-KRAS 2[Br
-] DTO, (green) highest loading ITO, and (orange) biotinylated probe 670 
compared to extractions (grey) without a DNA extraction probe from 10-fold diluted blood. 671 
[P6,6,6,14
+] [Mn(hfacac)3
-] MIL conditions: amount of [ADIM+]-KRAS 2[Br-] DTO relative to 672 
DNA: 5:1, amount of [AOIM+]-KRAS [PF6
-] ITO relative to DNA: 10:1, NaCl concentration: 25673 
mM, sample volume: 1.0 mL, extraction time: 3 min. [N8,8,8,Bz
+][Mn(hfacac)3
-] MIL conditions: 674 
amount of [ADIM+]-KRAS 2[Br-] DTO relative to DNA: 5:1, amount of [ABzIM+]-KRAS [Br-]  675 
relative to DNA: 10:1, NaCl concentration: 25 mM, sample volume: 1.0 mL, extraction time: 1 676 
min. Dynabeads M-270 Steptavidin magnetic beads conditi s: concentration of biotinylated 677 
probe: 332 fM, extraction time: 10 min; agitation rate: 250 rpm; desorption time: 10 min; 678 
desorption volume: 20 µL. 679 
 680 
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Highlights: 
 
• Mono- and disubstituted ion-tagged oligonucleotides used as DNA probes 
• Magnetic ionic liquid (MIL) solvents used to capture oligonucleotide probes 
• KRAS DNA was captured using probes and MIL from blood and plasma samples 
• Disubstituted oligonucleotide probes captured more DNA from diluted plasma and blood 
• Conventional streptavidin-coated magnetic beads were only selective after sample clean 
up steps 
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